Skip to content
LodeRx
Get started
Blog· glp-1· compounding· 503a

Compounded GLP-1s After the Shortage: What Current 503A Rules Mean for Access

The national GLP-1 shortage has ended. Here's what FDA's 503A rules actually allow now, who still qualifies for compounded access, and how to check your options.

9 min read

The Shortage Ended. What Happens to Your Prescription?

If you started a compounded semaglutide or tirzepatide prescription during 2023 or 2024, you may have heard that the shortage is over and wondered whether your prescription is still valid. The short answer: the blanket legal basis for shortage-based compounding has expired, but a narrower set of patient-specific exceptions still exists under federal law. This guide walks through what changed, what didn't, and what questions to bring to your clinician.

Table of contents

FDA Declared the National GLP-1 Shortage Resolved in 2025

The U.S. Food and Drug Administration removed semaglutide from its drug shortage list, and with it, the temporary legal basis that had allowed pharmacies to compound large volumes of the drug during the supply gap. According to Drug Topics (2025), 503A pharmacies were required to stop routine shortage-based compounding of semaglutide by April 22, 2025, and 503B outsourcing facilities had until May 22, 2025.

Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to make an "essential copy" of a commercially available drug only while that drug is officially listed as being in shortage. Once shortage status lifts, that exemption no longer applies as a general rule.

This does not mean compounded GLP-1s vanished overnight. It means the default legal basis for compounding them shifted from "the commercial product is unavailable" to something much narrower: an individual patient's documented clinical need.

What to remember: the end of the shortage did not end compounding outright. It ended the broad justification that let pharmacies compound GLP-1s as a stand-in for the commercial product, replacing it with case-by-case exceptions.

What Section 503A Still Permits for GLP-1 Compounding

Section 503A of the FD&C Act allows a state-licensed pharmacy or physician to compound a preparation for an individual, identified patient based on a valid prescription. FDA's April 2026 clarification on compounder policy, issued as national GLP-1 supply stabilized, outlines the conditions compounders must meet under both Sections 503A and 503B (fda.gov).

Outside of shortage conditions, that authority narrows considerably. A 503A pharmacy can no longer compound semaglutide or tirzepatide simply because a patient prefers a lower price point or wants to avoid a commercial product's injector device. Pharmacy Times (2026) reports that for 503A pharmacies specifically, narrow exceptions still exist, such as a documented excipient allergy or a need for a dose strength that isn't commercially manufactured.

The practical effect: compounding is still legally available, but it now requires a clinician to document a specific reason tied to that patient, not a general supply argument.

503A vs. 503B: Two Pathways With Different Rules

Not all compounding pharmacies operate under the same rules, and the post-shortage wind-down treated them differently. 503A pharmacies compound patient-specific prescriptions, typically in smaller batches, based on a prescription written for one named individual. 503B outsourcing facilities compound in bulk for clinics and hospitals, under stricter federal current Good Manufacturing Practice (CGMP) oversight, according to a 2024 compounding brief from Skadden (skadden.com).

The wind-down timelines also differed. 503A facilities were expected to stop shortage-based compounding essentially as soon as shortage status lifted, while 503B facilities operated under a longer transition window, per Skadden's analysis.

503A vs 503B Compounding: What Changed Post-Shortage

Pathway Compounding basis Post-shortage status Oversight
503A pharmacy Patient-specific prescription Compounding permitted only for individual clinical need or a documented, listed exception State board of pharmacy
503B outsourcing facility Office-use / bulk orders for clinics Required to cease shortage-based semaglutide and tirzepatide compounding after the wind-down window FDA, current Good Manufacturing Practice (CGMP)

The distinction matters if you're trying to understand why one clinic's compounding pathway looks different from another's. Ask which type of facility is actually filling your prescription; the answer changes what rules apply.

Narrow Exceptions That Still Allow a Compounded GLP-1 Prescription

Two categories of exception show up most often in current guidance:

  1. A documented allergy to an excipient. An excipient is a filler, preservative, or stabilizer used in the brand-name formulation, not the active drug itself. If a patient has a documented reaction to one of these inactive ingredients, a 503A pharmacy may compound an alternative formulation without that excipient, per Pharmacy Times (2026).
  2. A clinical need for a dose strength or formulation that isn't commercially available. Brand-name GLP-1 products come in a fixed set of dose strengths and delivery devices. When a prescriber documents that a patient's clinical situation requires something outside that fixed set, compounding may still apply.

Both exceptions share a common thread: they are patient-specific determinations, made by a licensed clinician who has reviewed that individual's history. Neither is a standing offer available to any interested patient, and neither substitutes for a general preference for compounded products over the commercial version.

What This Means If You Are Currently Using a Compounded GLP-1

If you're currently taking a compounded semaglutide or tirzepatide prescription, the practical next step is a conversation, not a guess. Ask your care team directly whether your prescription still fits one of the recognized 503A exceptions described above, or whether it was originally written under the now-expired shortage exemption.

GoodRx (2025) notes that compounded GLP-1s occupy a different regulatory category than the brand-name molecule and were never positioned as a permanent, interchangeable substitute for it. That distinction is worth sitting with: compounded and brand-name products are prepared, reviewed, and regulated differently, and neither the FDA nor a compounding pharmacy has ever described them as the same thing.

If your current prescription no longer fits a documented exception, your clinician can talk through two paths: transitioning to a brand-name GLP-1, or evaluating whether your specific clinical history supports one of the narrow exceptions that remain.

How LodeRx Structures Access to Compounded GLP-1s Today

LodeRx operates as a marketing brand; it does not practice medicine, dispense medication, or handle protected health information. Clinical evaluation is completed independently by EliteCare, a network of clinicians state-licensed across all 50 states.

When a compounded GLP-1 is clinically appropriate for an individual patient, the prescription is written by a licensed clinician and compounded and dispensed by RxAve and other 503A partner pharmacies, operating within the same 503A framework described throughout this article. That structure, a clinical evaluation on one side and a licensed 503A dispensing pathway on the other, is what separates a documented, patient-specific exception from a shortcut around it.

LodeRx also holds LegitScript Healthcare Merchant Certification, a healthcare compliance and merchant accreditation, not a medical endorsement and not FDA approval, applied to the marketing and platform side of the business.

For background on the intake process itself, see the loderx.com/glp-1 hub page, and the related loderx.com blog post on GLP-1 candidacy for a general overview of who typically moves forward to a clinical evaluation. The loderx.com compounding pathway explainer covers how the 503A process works in more detail.

Questions to Ask Before Starting or Continuing a Compounded GLP-1

Before you start, renew, or continue a compounded GLP-1 prescription, it's worth bringing a short list of questions to your clinician:

  • Does my situation match a documented 503A exception, such as an excipient allergy or an unavailable dose strength, rather than the expired shortage exemption?
  • Which pharmacy is compounding and dispensing my prescription, and is it a licensed 503A facility?
  • What does the intake process look like, and how are my health records handled?
  • Is there a brand-name option that fits my clinical picture better than a compounded formulation?
  • How will my dose or formulation be monitored over time, and by whom?

A clinician who reviews your history directly, not a general FAQ page, is the right party to answer these for your specific case.

FAQ

Can I still get compounded semaglutide now that the shortage has ended? Generally, routine shortage-based compounding of semaglutide stopped after FDA removed it from the shortage list in 2025. A 503A pharmacy can still compound it for an individual patient in narrow, documented circumstances, such as an excipient allergy or a medically necessary dose strength that isn't commercially available, per FDA and Pharmacy Times reporting.

Can you still get compounded tirzepatide in 2026? FDA's April 2026 clarification describes conditions compounders must meet under Sections 503A and 503B, and narrow exceptions remain for 503A pharmacies. Broad, shortage-based compounding of tirzepatide as a substitute for the commercial product is no longer the default legal pathway; a clinician determines whether an individual exception applies.

What is the difference between 503A and 503B compounding? A 503A pharmacy compounds a preparation for one identified patient based on a specific prescription. A 503B outsourcing facility compounds in larger batches for clinics and hospitals under stricter federal manufacturing oversight. Both operate under the FD&C Act, but the rules for shortage-based GLP-1 compounding and the wind-down timelines differed between the two.

Are compounded GLP-1s approved by the FDA? No. Only the brand-name GLP-1 molecules go through the FDA's drug approval process. Compounded formulations are prepared under the 503A or 503B compounding framework, a separate regulatory pathway. LegitScript certification, where it applies to a pharmacy or telehealth brand, is a compliance and merchant accreditation, not a medical endorsement or a substitute for FDA approval.

How do I know if my compounded GLP-1 prescription is still legal? Ask your prescribing clinician whether your prescription is based on a documented, patient-specific exception, like an allergy or unavailable dose strength, rather than the expired shortage exemption, and confirm the dispensing pharmacy is a licensed 503A facility. A clinician who reviews your history directly is best positioned to answer this for your specific case.

If you're unsure whether your current prescription still qualifies, or whether a compounded GLP-1 makes sense for your situation at all, the next concrete step is a clinical evaluation. EliteCare's state-licensed clinicians can review your history and discuss whether a documented exception applies, or whether a different path fits your case better.